SNAP-Tag-Based Antibody-Drug Conjugates Targeting Epidermal Growth Factor Receptor 1, Epidermal Growth Factor Receptor 2, Trophoblast Cell-Surface Antigen 2, and Tissue Factor for Ovarian Cancer Treatment. Here, TACSTD2 is linked to ovarian carcinoma.